Data are presented which show the potential for release of viable microorganisms into the atmosphere from high-vacuum steam sterilizers during the evacuation cycle preceding application of steam under pressure. Bacillus subtilis var. niger spores, Serratia marcescens cells, and T1 coliphage disseminated into the sterilizer chamber as small particles from liquid suspensions, and dried spores of B. subtilis var. niger distributed on bulk discard materials were recovered from the atmosphere around pipes venting steam from the steam ejectors used to create chamber vacuum. Evaluation of the hazard involved is discussed, and the design, fabrication, and installation of a valved filter system for preventing release of viable microorganisms are presented. The filtration system utilized an F-700 water-resistant filter and was shown to eliminate the release of viable airborne microorganisms from a high-vacuum sterilizer. A method is presented for determining size requirements for an atmospheric vent filter in relation to the volume of a sterilizer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC170381PMC
http://dx.doi.org/10.1128/aem.32.5.671-678.1976DOI Listing

Publication Analysis

Top Keywords

release viable
12
high-vacuum sterilizer
8
viable microorganisms
8
subtilis var
8
var niger
8
microbiological hazard
4
hazard exhaust
4
exhaust high-vacuum
4
sterilizer
4
sterilizer data
4

Similar Publications

Glioblastoma multiforme (GBM) is characterized by pronounced immune escape and resistance to chemotherapy-induced apoptosis. Preliminary investigations revealed a marked overexpression of gasdermin E (GSDME) in GBM. Notably, cisplatin (CDDP) demonstrated a capacity of inducing pyroptosis by activating caspase-3 to cleave GSDME, coupled with the release of proinflammatory factors, indicating the potential as a viable approach of inducing anti-tumor immune activation.

View Article and Find Full Text PDF

Counteracting Alzheimer's disease normalizing neurovascular unit with a self-regulated multi-functional nano-modulator.

Acta Pharm Sin B

December 2024

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Mental Health Center and National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, China.

The neurovascular unit (NVU) is highly responsible for cerebral homeostasis and its dysfunction emerges as a critical contributor to Alzheimer's disease (AD) pathology. Hence, rescuing NVU dysfunction might be a viable approach to AD treatments. Here, we fabricated a self-regulated muti-functional nano-modulator (siR/PIO@RP) that can intelligently navigate to damaged blood-brain barrier and release therapeutical cargoes for synergetic AD therapy.

View Article and Find Full Text PDF

Background: Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL.

Methods: A systematic literature search of PubMed, Cochrane, Embase, ClinicalTrials.

View Article and Find Full Text PDF

Corneal first aid lens: Collagen-based hydrogels loading aFGF as contact lens for treating corneal injuries.

J Control Release

January 2025

Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Cixi Biomedical Research Institute, School of Pharmaceutical Sciences, Wenzhou Medical University, Ningbo, China. Electronic address:

Severe corneal injuries can cause visual impairment even blindness. Surgically stitching or implanting biomaterials have been developed, but their implementation requires professional surgeons, failing to address the immediate need of medical treatment. The pressing challenge lies in developing multifunctional biomaterials that enable self-management of corneal injuries.

View Article and Find Full Text PDF
Article Synopsis
  • FT596 is a novel cancer therapy using iPSC-derived CAR NK cells targeting CD19, designed to assess its safe dosage and effectiveness alone and with rituximab in patients with B-cell lymphoma.
  • This phase 1 trial involved patients with relapsed or refractory B-cell lymphoma, administering FT596 after chemotherapy, with separate regimens for those receiving rituximab and those who did not.
  • The study measured potential side effects while determining the optimal dose of FT596 and allowed modifications to the treatment based on patient tolerance and response.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!